N
NeuSpera Medical
NeuSpera, formerly known as Vivonda Medical, is developing injectable neuromodulation devices, so called “electroceuticals
About NeuSpera Medical
Neuspera is a medical technology startup that specializes in developing innovative solutions for individuals suffering from Urinary Urgency Incontinence (UUI), a symptom of Overactive Bladder (OAB). The company's flagship product is the Neuspera Implantable Sacral Neuromodulation (SNM) System, a minimally invasive device designed to improve bladder control. The system includes an ultra-miniaturized implant and a wearable external transmitter that powers the implant wirelessly.
Read full description
The company's business model revolves around the sale of these devices to patients through healthcare providers. The implantable device is powered by Neuspera's proprietary Mid-Field Powering technology, which uses the body's natural composition to efficiently focus power to the implant from the external transmitter. This technology offers a less complicated alternative to traditional treatments for UUI, providing patients with a more convenient and comfortable solution.
Neuspera operates in the medical technology market, specifically targeting individuals suffering from UUI. The company's patient-first approach and innovative technology have positioned it as a potential leader in this niche market. Neuspera generates revenue through the sale of its SNM system to healthcare providers, who then offer the treatment to their patients.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- San Jose, United States
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 30.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Tech for Patients, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning NeuSpera Medical.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jul 2024 | $23M | $325M | Olympus · Vertex Holdings · Windham Venture Partners · Action Potential Venture Capital | ↗ |
| FundingOther financing | May 2024 | $0 | — | MedTech Innovator | ↗ |
Growth signals
Latest recorded traffic for NeuSpera Medical is 1.7K monthly website visits, up 54.5% over the last three months. NeuSpera Medical's team declined 2.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Windham Venture Partners
Purple Arch Ventures (an Alumni Ventures Fund)
Action Potential Venture Capital
Alumni Ventures
6 Dimensions Capital
Series B and later4 investors entered at this stage
Treo Ventures
Vertex Ventures HC
Vertex Holdings
Olympus
Other known investors1 additional known investor
MedTech Innovator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuSpera Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuSpera Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.